Oncologie and Merck Collaborate to Evaluate Bavituximab + Keytruda for Treatment of Advanced Gastric or Gastroesophageal Cancer

 Oncologie and Merck Collaborate to Evaluate Bavituximab + Keytruda for Treatment of Advanced Gastric or Gastroesophageal Cancer

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Shots:

  • Oncologie to conduct P-II study assessing the efficacy and safety of Bavituximab in combination with Merck’s Keytruda (pembrolizumab) in patients with 1L advanced gastric or gastroesophageal cancer enrolling ~80 patients in the US, UK, Korea and Taiwan with expected enrollment in H2’19
  • The focus of the collaboration is to evaluate the combination Keytruda and Bavituximab for getting better insights of cancer further improving QoL
  • Bavituximab is a chimeric mAb targeting the activity of phosphatidylserine (PS) and has shown safety and tolerability in multiple clinical trials. Keytruda is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post